Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly is expanding the ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

Bitcoin has fluctuated within a narrow range in recent sessions, reflecting investor caution in an uncertain macroeconomic environment. Along with the heightened trade tensions, the outlook for Fed ...

Is US president Donald Trump opening the door to a wider global trade war – one that could have dire consequences for the ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

At 11:26 a.m. ET, the Dow Jones Industrial Average fell 75.92 points, or 0.17%, to 44,797.36, the S&P 500 gained 14.66 points ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Wall Street is drifting as drops for Ford Motor and Qualcomm work against buoyant fashion and cigarette stocks. The S&P 500 slipped 0.1% Thursday following healthy gains for stock markets ...

Wall Street drifted through a mixed day of trading as rising fashion and cigarette stocks worked against drops for Ford Motor ...

Wall Street is drifting Thursday as gains for fashion brands and cigarette makers help offset drops for Ford Motor and ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...